Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 2005

View Archived Issues

Peregrine signs licensing agreement with Medarex for vascular targeting agents

New preclinical data support use of OXI-4503 in cancer

Inyx to acquire Celltech Manufacturing Services from UCB

EncorePharma receives phase I SBIR grant for Huntington's disease research

Acambis on track to begin phase III trials of ChimeriVax-JE by year-end

AL-208 enters phase I trials for MCI associated with CABG

Sunesis selects Aurora kinase candidate for preclinical development

New study evaluates Cotara for glioblastoma multiforme

Advaxis completes preclinical toxicology studies for Lovaxin C

SCOLR Pharma completes pilot bioavailability testing of CDT-raloxifene

Enrollment completed in phase II study of ozarelix for prostate cancer

Discovery receives FDA notification regarding Surfaxin response letter

Positive findings in open-label study of Prestara

Preclinical profile of AMG-8163 for the treatment of pain

Preclinical summary on ONO-2921, a Cav2.2 blocker for pain

Actoplus Met approved for type 2 diabetes

sBLA filed for Erbitux for head and neck cancer

New data on Remune presented

CHIR-258 active against acute myelogenous leukemia cells in vitro and in vivo

Novel BK-1 antagonist with high selectivity and good PK profile

TAK-242 subject of presentation at ACS meeting

Maraviroc reported safe and effective in HIV infection

EGIS-11229: A novel noncompetitive AMPA receptor antagonist

Case report: Reboxetine induces weight loss

Recent patents describe novel antiinfective agents

New potential treatments for obesity emerge from pharmaceutical R&D

Novel agents for thrombotic disorders imparted by AstraZeneca

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...